Donald L. Hagan, LLC Abb Vie Inc. Transaction History

Donald L. Hagan, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 18, 2022	SELL	$131.98 - $163.75 $712,296 - $883,758	-5,397 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$107.43 - $135.93 $9,131 - $11,554	85 Added 1.6%	5,397 $731,000
Q3 2021 Oct 20, 2021	SELL	$106.4 - $120.78 $206,735 - $234,675	-1,943 Reduced 26.78%	5,312 $573,000
Q2 2021 Jul 19, 2021	SELL	$105.21 - $117.21 $2,840 - $3,164	-27 Reduced 0.37%	7,255 $817,000
Q1 2021 Apr 27, 2021	SELL	$102.3 - $112.62 $311,810 - $343,265	-3,048 Reduced 29.51%	7,282 $788,000
Q4 2020 Jan 15, 2021	SELL	$80.49 - $108.67 $93,690 - $126,491	-1,164 Reduced 10.13%	10,330 $1.11 Million
Q3 2020 Oct 16, 2020	SELL	$85.91 - $100.83 $467,694 - $548,918	-5,444 Reduced 32.14%	11,494 $1.01 Million
Q2 2020 Aug 03, 2020	SELL	$73.37 - $98.18 $182,030 - $243,584	-2,481 Reduced 12.78%	16,938 $1.66 Million
Q1 2020 Apr 17, 2020	BUY	$64.5 - $97.79 $1.25 Million - $1.9 Million	19,419 New	19,419 $1.59 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Donald L. Hagan, LLC, based on Form 13F filings with the SEC.

Stay updated on Donald L. Hagan, LLC with notifications on news.